Serum CA19–9 Alterations During Preoperative Gemcitabine-Based Chemoradiation Therapy for Resectable Invasive Ductal Carcinoma of the Pancreas as an Indicator for Therapeutic Selection and Survival-Reference-Cited by-同舟云学术

Serum CA19–9 Alterations During Preoperative Gemcitabine-Based Chemoradiation Therapy for Resectable Invasive Ductal Carcinoma of the Pancreas as an Indicator for Therapeutic Selection and Survival

Published:2010-03 Issue:3 Volume:251 Page:461-469
ISSN:0003-4932
Container-title:Annals of Surgery
language:en
Short-container-title:

Author:

Takahashi Hidenori,Ohigashi Hiroaki,Ishikawa Osamu,Eguchi Hidetoshi,Gotoh Kunihito,Yamada Terumasa,Nakaizumi Akihiko,Uehara Hiroyuki,Tomita Yasuhiko,Nishiyama Kinji,Yano Masahiko

Publisher

Ovid Technologies (Wolters Kluwer Health)

Subject

Surgery

Reference39 articles.

1. Cancer statistics, 2008.;Jemal;CA Cancer J Clin,2008

2. Recent major progress in long-term cancer patient survival disclosed by modeled period analysis.;Brenner;J Clin Oncol,2007

3. Preoperative gemcitabine-based chemoradiation for patients with resectable adenocarcinoma of the pancreatic head.;Evans;J Clin Oncol,2008

4. Preoperative chemoradiation in adenocarcinoma of the pancreas. A single centre experience advocating a new treatment strategy.;Golcher;Eur J Surg Oncol,2008

5. Feasibility and efficacy of combination therapy with preoperative full-dose gemcitabine, concurrent three-dimensional conformal radiation, surgery, and postoperative liver perfusion chemotherapy for T3-pancreatic cancer.;Ohigashi;Ann Surg,2009

Cited by 63 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Results of a Randomized Clinical Study of Gemcitabine Plus Nab-Paclitaxel Versus Gemcitabine Plus S-1 as Neoadjuvant Chemotherapy for Resectable and Borderline Resectable Pancreatic Ductal Adenocarcinoma (RCT, CSGO-HBP-015);Annals of Surgical Oncology;2024-03-28

2. Prognostic Significance of Biologic Factors in Patients with a Modest Radiologic Response to Neoadjuvant Treatment for Resectable and Borderline Resectable Pancreatic Cancers: Impact of the Combination Index of Sialyl-Lewis Antigen-Related Tumor Markers;Annals of Surgical Oncology;2024-02-17

3. ASO Author Reflections: A Novel Combination Index of Sialyl-Lewis Antigen-Related Tumor Markers Enhances Predictive Significance in Patients with a Modest Radiological Response to Neoadjuvant Treatment for Pancreatic Cancer;Annals of Surgical Oncology;2024-02-16

4. Pathological Nodal and Vascular Involvement Significantly Impacts the Recurrence Risk in Different Time Frames in Patients With Resectable and Borderline Resectable Pancreatic Cancer;Annals of Surgery;2023-04-14

5. DUPAN-II normalisation as a biological indicator during preoperative chemoradiation therapy for resectable and borderline resectable pancreatic cancer;BMC Cancer;2023-01-18